Quarterly report [Sections 13 or 15(d)]

OPERATING SEGMENT (Tables)

v3.25.1
OPERATING SEGMENT (Tables)
3 Months Ended
Mar. 31, 2025
OPERATING SEGMENT  
Schedule of financial data for the one reportable segment

Three Months Ended March 31,

    

2025

    

2024

Research and development:

Phase 2 study in WM

$

633,000

$

2,194,000

Phase 1 study in pediatric tumors

 

733,000

 

499,000

Manufacturing and related costs

 

709,000

 

3,313,000

Pre-clinical projects costs

 

507,000

 

21,000

General research and development costs

 

845,000

 

1,061,000

General and administrative

 

2,974,000

 

4,913,000

Other segment items

 

203,000

 

14,641,000

Segment and consolidated net loss

$

6,604,000

$

26,642,000